Global Next Generation Multispecific Antibody Market Size Clinical Trials FDA Approval Market Forecast Insight

Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029 Report Highlights:

• Global & Regional Market Analysis
• Global Multispecific Antibodies Market Opportunity: > USD 40 Billion
• Global Multispecific Antibodies Market Sales In 2023: > USD 8 Billion
• Number Of Approved Multispecific Antibodies: 14 Antibodies
• Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight
• Approved Antibodies Dosage & Pricing Insight
• Number Of Multispecific Antibodies: In Clinical Trials: > 900
• Comprehensive Insight On All Antibodies In Clinical Trials By Company, Country, Indication, & Phase

Download Report:

https://www.kuickresearch.com/report-multispecific-antibodies-market-multispecific-antibody-market-clinical-trials-clinical-research

The pursuit of curing cancer and other malignancies has evolved significantly since researchers first conceptualized immunotherapy over the past two decades. This progression has resulted in the development of next-generation multispecific antibodies, including bispecific, trispecific, and tetraspecific antibodies. With numerous bispecific antibodies receiving approval in recent years, the landscape of treatment with next-generation multispecific antibodies is generating considerable interest within the lucrative pharmaceutical industry. Many of these therapies, such as Hemlibra, have become blockbusters, generating billions of dollars in annual sales. Their effectiveness and favorable safety profiles have contributed to their widespread acceptance in the market.

According to KuicK Research, the market size for next-generation multispecific antibodies was approximately US$ 9 billion in 2023 and is expected to grow substantially over the next 2 to 5 years. Additionally, our analysis indicates that more than 900 next-generation multispecific antibodies are currently in clinical trials or at the preclinical stage. This presents a profitable market opportunity in this segment, and as a result, the global market for next-generation multispecific antibodies is intensifying year by year.

From a market perspective, Hemlibra, co-developed internationally by Chugai Pharmaceuticals, Roche, and Genentech, is one of the highest-selling drugs, capturing over 50% of the market share for next-generation multispecific antibodies in both 2023 and 2022. Given their multibillion-dollar potential, many pharmaceutical companies are actively investing in this space. Notable players, including Novartis, Roche, Johnson & Johnson, Merus, Merck, AbCellera Biologics, Zymeworks, Amgen, and Ichnos Sciences, a subsidiary of Simcere Pharmaceutical Group, are eagerly involved in the development of next-generation multispecific antibodies as potential game-changer candidates.

Several key factors are driving the global market for next-generation multispecific antibodies, including the rising incidence of cancer, technological advancements in the field, stakeholder involvement, and research collaborations. For instance, in April 2024, Invenra, a US biotech company, partnered with Japanese giant Astellas Pharma to focus on developing therapeutic bispecific antibodies. Under this collaboration, both companies will leverage each other's platforms and technologies to discover innovative bispecific antibodies. Similarly, in December 2023, Celltrion, a South Korean biopharmaceutical company, joined forces with Cyron to develop a new multispecific antibody over a three-year period.

As of September 2024, 14 next-generation multispecific antibodies, including Blincyto, Hemlibra, Rybrevant, Vabysmo, Tecvayli, and Columvi, have been launched into the market. Looking ahead, we anticipate that the future outlook for this segment is promising, with more than three next-generation multispecific antibodies likely to enter the global commercial market within the next 5 to 7 years. For example, in 2024, next-generation multispecific antibodies such as zenocutuzumab (HER2 x HER3), Linvoseltamab (BCMA x CD3), and Zanidatamab, a HER2-targeted biparatopic bispecific antibody, have received FDA Biologics License Applications (BLAs) and are expected to launch in the global market soon.

In conclusion, the global multispecific antibody segment appears to be thriving, with several new candidates anticipated to enter the market in the next five years. Currently, the US leads the next-generation multispecific antibody market due to higher sales, increasing approvals, supportive government policies, and the presence of major pharmaceutical companies. The pursuit of next-generation multispecific antibodies extends beyond laboratory research, embodying a collective vision to redefine treatment paradigms for patients facing significant challenges from cancer, autoimmune diseases, and other disorders.

KuicK Research
Delhi
India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.